应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BGNE 百济神州
已收盘 03-28 16:00:00 EDT
156.39
+1.31
+0.84%
盘后
156.39
+0.00
0.00%
16:01 EDT
最高
157.38
最低
155.09
成交量
10.41万
今开
157.00
昨收
155.08
日振幅
1.48%
总市值
163.31亿
流通市值
91.42亿
总股本
1.04亿
成交额
1,629万
换手率
0.18%
流通股本
5,845万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
【港股通】百济神州(06160)去年净亏损收窄56%至8.82亿美元 不派息
金吾资讯 · 03-28 23:43
【港股通】百济神州(06160)去年净亏损收窄56%至8.82亿美元 不派息
百济神州:2023年净亏损8.82亿美元,亏损额同比减少约56%
界面 · 03-28 20:07
百济神州:2023年净亏损8.82亿美元,亏损额同比减少约56%
百济神州:2023年净亏损8.89亿元
财通社 · 03-28 19:03
百济神州:2023年净亏损8.89亿元
百济神州(06160)发布年度业绩 毛利20.79亿美元 同比增加84.06% 巩固了在血液肿瘤领域的领导地位
智通财经 · 03-28 18:37
百济神州(06160)发布年度业绩 毛利20.79亿美元 同比增加84.06% 巩固了在血液肿瘤领域的领导地位
百济神州诉外企侵犯专利 国内药企要学新的一课
经济观察网 · 03-27 17:20
百济神州诉外企侵犯专利 国内药企要学新的一课
百济神州3月26日获南向资金加仓54.59万股
自选股智能写手 · 03-27 09:31
百济神州3月26日获南向资金加仓54.59万股
百济神州(苏州)生物科技有限公司申请III类会议
金融界 · 03-26
百济神州(苏州)生物科技有限公司申请III类会议
医药行业周报:安进/百济神州双抗疗法在中国启动3期临床
太平洋证券股份... · 03-26
医药行业周报:安进/百济神州双抗疗法在中国启动3期临床
百济神州上涨2.24%,报155.42美元/股
金融界 · 03-25
百济神州上涨2.24%,报155.42美元/股
创新药融资承压,百济神州还能跨过盈亏平衡线吗?
松果财经 · 03-25
创新药融资承压,百济神州还能跨过盈亏平衡线吗?
中国新药杀疯了
虎嗅APP · 03-23
中国新药杀疯了
百济神州(06160)股价下跌8.095%,现价港币$93.1
阿斯达克财经 · 03-22
百济神州(06160)股价下跌8.095%,现价港币$93.1
百济神州(06160)下跌5.03%,报96.2元/股
金融界 · 03-22
百济神州(06160)下跌5.03%,报96.2元/股
百济神州获融资买入0.13亿元,近三日累计买入0.28亿元
金融界 · 03-22
百济神州获融资买入0.13亿元,近三日累计买入0.28亿元
百济神州(06160):Olivier Brandicourt获委任为商业及医学事务咨询委员会成员
智通财经 · 03-21
百济神州(06160):Olivier Brandicourt获委任为商业及医学事务咨询委员会成员
北向资金3月20日净卖出百济神州-U1.20万股 连续3日减持
自选股智能写手 · 03-21
北向资金3月20日净卖出百济神州-U1.20万股 连续3日减持
百济神州获北向资金卖出2214.5万元,累计持股475.9万股
金融界 · 03-20
百济神州获北向资金卖出2214.5万元,累计持股475.9万股
百济神州(06160)出现大手卖出10万股,成交价$101.95,涉资1.02千万
阿斯达克财经 · 03-18
百济神州(06160)出现大手卖出10万股,成交价$101.95,涉资1.02千万
美银证券:重申百济神州(06160)“中性”评级 目标价升至108.27港元
智通财经 · 03-18
美银证券:重申百济神州(06160)“中性”评级 目标价升至108.27港元
加载更多
公司概况
公司名称:
百济神州
所属市场:
NASDAQ
上市日期:
--
主营业务:
百济神州有限公司是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物,主要产品百悦泽((BRUKINSA),BTK抑制剂)、百泽安(抗PD-1单抗)、帕米帕利。公司自主研发产品BRUKINSA(百悦泽)实现了中国原研新药出海的“零突破”,并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年,公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外,公司作为承担单位进行了5项国家级科研项目,并在核心期刊上发表了34篇学术论文。
发行价格:
--
{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":156.39,"timestamp":1711656000000,"preClose":155.08,"halted":0,"volume":104129,"hourTrading":{"tag":"盘后","latestPrice":156.39,"preClose":156.39,"latestTime":"16:01 EDT","volume":3706,"amount":579581.34,"timestamp":1711656080991},"delay":0,"floatShares":58454487,"shares":104427730,"eps":-8.446508,"marketStatus":"已收盘","marketStatusCode":5,"change":1.31,"latestTime":"03-28 16:00:00 EDT","open":157,"high":157.38,"low":155.09,"amount":16289284.7473,"amplitude":0.014767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.446508,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1711958400000},"adr":1,"adjPreClose":155.08,"adrRate":13,"preHourTrading":{"tag":"盘前","latestPrice":155.14,"preClose":155.08,"latestTime":"08:43 EDT","volume":6,"amount":930.8399999999999,"timestamp":1711629796504},"postHourTrading":{"tag":"盘后","latestPrice":156.39,"preClose":156.39,"latestTime":"16:01 EDT","volume":3706,"amount":579581.34,"timestamp":1711656080991},"volumeRatio":0.552875},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2422114536","title":"【港股通】百济神州(06160)去年净亏损收窄56%至8.82亿美元 不派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2422114536","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422114536?lang=zh_cn&edition=full","pubTime":"2024-03-28 23:43","pubTimestamp":1711640639,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 公告,截至2023年12月31日止年度,净亏损减少56%至8.82亿美元。每股基本亏损0.65美元,同比减少56.4%。期内,收入合计同比增长约73.65%至24.59亿美元。主要是由于公司的自主研发产品百悦泽和百泽安的销售额增加,以及授权许可产品的销售额增加,其中增长最明显的是安进产品和普贝希。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032823440987c14587&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032823440987c14587&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422316772","title":"百济神州:2023年净亏损8.82亿美元,亏损额同比减少约56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422316772","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2422316772?lang=zh_cn&edition=full","pubTime":"2024-03-28 20:07","pubTimestamp":1711627627,"startTime":"0","endTime":"0","summary":"百济神州3月28日公告,截至2023年12月31日止年度的收入合计较截至2022年12月31日止年度增加约10亿美元或约73.7%至约25亿美元。截至2023年12月31日止年度的净亏损较截至2022年12月31日止年度减少约11亿美元或约56.0%至约8.82亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328200707791d94f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328200707791d94f0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422116935","title":"百济神州:2023年净亏损8.89亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422116935","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2422116935?lang=zh_cn&edition=full","pubTime":"2024-03-28 19:03","pubTimestamp":1711623780,"startTime":"0","endTime":"0","summary":"百济神州公告,截至2023年12月31日止年度的净亏损较截至2022年12月31日止年度减少约11亿美元或约56.0%至约8.89亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032819041887c06485&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032819041887c06485&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422163102","title":"百济神州(06160)发布年度业绩 毛利20.79亿美元 同比增加84.06% 巩固了在血液肿瘤领域的领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2422163102","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422163102?lang=zh_cn&edition=full","pubTime":"2024-03-28 18:37","pubTimestamp":1711622246,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百济神州 发布截至2023年12月31日止年度全年业绩,该集团期内取得收入合计24.59亿美元,同比增加73.65%;毛利20.79亿美元,同比增加84.06%;研发费用17.79亿美元,同比增加8.42%。公告称,随着百悦泽在全球特别是在美国和欧洲市场上市的持续成功,集团巩固了在血液肿瘤领域的领导地位。截至2023年12月31日止年度,百悦泽在中国的销售额总计1.938亿美元,同比增长28.9%,得益于所有获批适应症的销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094953.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422950333","title":"百济神州诉外企侵犯专利 国内药企要学新的一课","url":"https://stock-news.laohu8.com/highlight/detail?id=2422950333","media":"经济观察网","top":-1,"share":"https://www.laohu8.com/m/news/2422950333?lang=zh_cn&edition=full","pubTime":"2024-03-27 17:20","pubTimestamp":1711531209,"startTime":"0","endTime":"0","summary":"3月下旬,接近百济神州专利诉讼事件的人士告诉经济观察网。去年6月,美国药企艾伯维旗下公司Pharmacyclics指控泽布替尼侵犯其伊布替尼专利,并已在美国地方法院提起诉讼。作为拥有国内第一个“十亿美元分子”的药企,百济神州无论是发起专利诉讼,还是应诉专利侵权指控,都是成长路上必须面对的功课。百济神州认为,山德士和MSN提交ANDA侵犯了橙皮书专利,并寻求永久禁令,以阻止两家公司商业化泽布替尼的仿制药。百济神州在公告中称。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032717252187bbbc58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032717252187bbbc58&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422010356","title":"百济神州3月26日获南向资金加仓54.59万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422010356","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422010356?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:31","pubTimestamp":1711503071,"startTime":"0","endTime":"0","summary":"3月26日, 南向资金增持百济神州54.59万股。截止当日收盘,港股通共持有百济神州5143.23万股,占流通股3.77%。百济神州近5个交易日下跌8.01%,港股通累计增持102.19万股;近20个交易日下跌5.50%,港股通累计增持225.55万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270943478b678e28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270943478b678e28&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422570699","title":"百济神州(苏州)生物科技有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2422570699","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422570699?lang=zh_cn&edition=full","pubTime":"2024-03-26 06:41","pubTimestamp":1711406494,"startTime":"0","endTime":"0","summary":"金融界3月26日消息,据CDE官网沟通交流公示,于3月26日收到百济神州(苏州)生物科技有限公司申请的“III类会议”,当前状态“处理中”。根据《药物研发与技术审评沟通交流管理办法》(2020年第48号通告),沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议,就关键阶段重大问题进行沟通交流,Ⅲ类会议一般安排在申请后75日内召开。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260641378b62b078&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260641378b62b078&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422687793","title":"医药行业周报:安进/百济神州双抗疗法在中国启动3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2422687793","media":"太平洋证券股份...","top":-1,"share":"https://www.laohu8.com/m/news/2422687793?lang=zh_cn&edition=full","pubTime":"2024-03-26 00:00","pubTimestamp":1711382400,"startTime":"0","endTime":"0","summary":"行业要闻:近日,中国药物临床试验登记与信息公示平台官网显示,安进和百济神州共同启动了一项国际多中心(含中国)3 期临床研究,以评价局限期小细胞肺癌放化疗后进行Tarlatamab 治疗的有效性和安全性,该药为一款靶向DLL3 和CD3 的双特异性T 细胞衔接蛋白,百济神州拥有该药的中国商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261129288b63975c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261129288b63975c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422188544","title":"百济神州上涨2.24%,报155.42美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422188544","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422188544?lang=zh_cn&edition=full","pubTime":"2024-03-25 23:11","pubTimestamp":1711379491,"startTime":"0","endTime":"0","summary":"3月25日,百济神州(BGNE)盘中上涨2.24%,截至23:11,报155.42美元/股,成交663.5万美元。财务数据显示,截至2023年12月31日,百济神州收入总额24.59亿美元,同比增长73.65%;归母净利润-8.82亿美元,同比增长56.0%。大事提醒:5月2日,百济神州将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/25231139986664.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422173580","title":"创新药融资承压,百济神州还能跨过盈亏平衡线吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2422173580","media":"松果财经","top":-1,"share":"https://www.laohu8.com/m/news/2422173580?lang=zh_cn&edition=full","pubTime":"2024-03-25 09:34","pubTimestamp":1711330482,"startTime":"0","endTime":"0","summary":"以百济神州为例。2023年,百济神州营收同比增速达到了惊人的74%。显然,资本希望创新药企能更好地平衡规模和盈利之间的关系。但由于创新药是技术密集型、人才密集型的行业,百济神州2023年包括研发费用、销售及管理费用、无形资产摊销三项在内的经营费用仍然同比增长12.6%。近日,百济神州宣布百泽安将于2024年下半年在美国上市,这是第二款在美成功获批的国产PD-1,有较大可能成为百济神州的“第二支柱”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403250935028b5f001f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403250935028b5f001f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421334643","title":"中国新药杀疯了","url":"https://stock-news.laohu8.com/highlight/detail?id=2421334643","media":"虎嗅APP","top":-1,"share":"https://www.laohu8.com/m/news/2421334643?lang=zh_cn&edition=full","pubTime":"2024-03-23 16:39","pubTimestamp":1711183164,"startTime":"0","endTime":"0","summary":"出品 | 虎嗅医疗组作者 | 陈广晶编辑 | 王一鹏头图 | 视觉中国中国新药杀疯了。“11:0全票通过!”美国FDA肿瘤药物咨询委员会(ODAC)全票认可了西达基奥仑赛安全有效性评估结果,北京时间3月16日凌晨3点50分,传奇生物通过官方微信公众号第一时间分享了这一喜讯。全票通过的结果,不仅意味着,西达基奥仑赛或将很快获批用...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OTKcWa_vZKYCrlu73giGIw2jiP9AHZZ6Fb2tvtmhq_KdoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OTKcWa_vZKYCrlu73giGIw2jiP9AHZZ6Fb2tvtmhq_KdoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240323A05W0800","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240323A05W0800","is_publish_highlight":false,"gpt_icon":0},{"id":"2421183140","title":"百济神州(06160)股价下跌8.095%,现价港币$93.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2421183140","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2421183140?lang=zh_cn&edition=full","pubTime":"2024-03-22 11:56","pubTimestamp":1711079760,"startTime":"0","endTime":"0","summary":"[下跌股]百济神州(06160) 股价在上午11:56比前收市价下跌8.095%,现股价为港币$93.1。至目前为止,今日最高价为$99.25,而最低价为$93.1。总成交量为74.3万股,总成交金额为港币$7.14千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2403224826/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2421882338","title":"百济神州(06160)下跌5.03%,报96.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421882338","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421882338?lang=zh_cn&edition=full","pubTime":"2024-03-22 10:06","pubTimestamp":1711073192,"startTime":"0","endTime":"0","summary":"3月22日,百济神州(06160)盘中下跌5.03%,截至10:06,报96.2元/股,成交3003.79万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合,以及超过1300名员工的全球团队。截至2023年年报,百济神州营业总收入174.15亿元、净利润-62.45亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/22100639951105.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421007729","title":"百济神州获融资买入0.13亿元,近三日累计买入0.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421007729","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421007729?lang=zh_cn&edition=full","pubTime":"2024-03-22 08:21","pubTimestamp":1711066908,"startTime":"0","endTime":"0","summary":"3月21日,沪深两融数据显示,百济神州获融资买入额0.13亿元,居两市第728位,当日融资偿还额0.11亿元,净买入188.21万元。最近三个交易日,19日-21日,百济神州分别获融资买入0.07亿元、0.09亿元、0.13亿元。融券方面,当日融券卖出2.82万股,净卖出2.29万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220821548b52dbd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220821548b52dbd8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421091690","title":"百济神州(06160):Olivier Brandicourt获委任为商业及医学事务咨询委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2421091690","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421091690?lang=zh_cn&edition=full","pubTime":"2024-03-21 17:46","pubTimestamp":1711014411,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百济神州(06160)发布公告,自2024年3月19日(美国东部时间)起,公司独立非执行董事Olivier Brandicourt获委任为董事会商业及医学事务咨询委员会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1089835.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421033716","title":"北向资金3月20日净卖出百济神州-U1.20万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2421033716","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421033716?lang=zh_cn&edition=full","pubTime":"2024-03-21 09:30","pubTimestamp":1710984630,"startTime":"0","endTime":"0","summary":"3月20日,北向资金减持百济神州-U1.20万股连续3日减持。截止当日收盘,沪股通共持有百济神州-U474.70万股,占流通股4.12%。百济神州-U近5个交易日上涨9.46%,沪股通累计增持47.53万股;近20个交易日上涨20.05%,沪股通累计增持326.97万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321093517879f66e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321093517879f66e8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420392739","title":"百济神州获北向资金卖出2214.5万元,累计持股475.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420392739","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420392739?lang=zh_cn&edition=full","pubTime":"2024-03-20 08:31","pubTimestamp":1710894709,"startTime":"0","endTime":"0","summary":"3月20日,巨灵财经数据显示,北向资金19日减持百济神州预估2214.5万元,累计持股475.9万股,总计持有市值6.65亿元,占流通股比例4.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320083150879a4217&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320083150879a4217&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420419453","title":"百济神州(06160)出现大手卖出10万股,成交价$101.95,涉资1.02千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2420419453","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420419453?lang=zh_cn&edition=full","pubTime":"2024-03-18 13:34","pubTimestamp":1710740040,"startTime":"0","endTime":"0","summary":"[大手成交]百济神州(06160)在下午01:34出现大手卖出,成交量为10万,成交价为港币$101.95,涉资1.02千万。至目前为止,股价跌1.731%,今日最高价为$104.0,而最低价为$99.85,总成交量为115.992万股,总成交金额港币$1.174亿。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2403182317/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2420949755","title":"美银证券:重申百济神州(06160)“中性”评级 目标价升至108.27港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420949755","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420949755?lang=zh_cn&edition=full","pubTime":"2024-03-18 11:54","pubTimestamp":1710734049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,美银证券发布研究报告称,应百济神州(06160)收入变化,将2024至2026年的每股盈利预测分别调整-3%/100%/4%。鉴于公司药物管道开发进展顺利,将百济神州目标价由103.5港元上调至108.27港元,并重申“中性”评级。该行指出,因应美国食品药物管理局(FDA)批准使用百济神州开发的替雷利珠单抗,而且相关药物于1月份的样品销售表现犟劲,该行将公司2024年至2026年的整体营业收入预测分别上调0.9%/1.2%/0.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087633.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0857},{"period":"1month","weight":-0.0323},{"period":"3month","weight":-0.1359},{"period":"6month","weight":-0.1378},{"period":"1year","weight":-0.295},{"period":"ytd","weight":-0.1402}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0975},{"period":"6month","weight":0.2238},{"period":"1year","weight":0.3225},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":" 百济神州有限公司是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物,主要产品百悦泽((BRUKINSA),BTK抑制剂)、百泽安(抗PD-1单抗)、帕米帕利。公司自主研发产品BRUKINSA(百悦泽)实现了中国原研新药出海的“零突破”,并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年,公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外,公司作为承担单位进行了5项国家级科研项目,并在核心期刊上发表了34篇学术论文。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.029811},{"month":4,"riseRate":0.5,"avgChangeRate":0.034245},{"month":5,"riseRate":0.5,"avgChangeRate":-0.012888},{"month":6,"riseRate":0.625,"avgChangeRate":0.022561},{"month":7,"riseRate":0.75,"avgChangeRate":0.132564},{"month":8,"riseRate":0.5,"avgChangeRate":0.021799},{"month":9,"riseRate":0.5,"avgChangeRate":0.051436},{"month":10,"riseRate":0.625,"avgChangeRate":0.017618},{"month":11,"riseRate":0.5,"avgChangeRate":0.059889},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}